Elicio Therapeutics Inc. Cash Flow-to-Debt Ratio
Elicio Therapeutics Inc. cash flow-to-debt ratio. Elicio Therapeutics Inc. (ELTX) has a Cash Flow-to-Debt Ratio of -0.35x as of June 2026, meaning its operating cash flow of $-8.16 Million could theoretically repay 0% of its total liabilities ($23.39 Million) in one year. Check ELTX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Elicio Therapeutics Inc. (2012–2025)
Cash flow-to-debt ratio of Elicio Therapeutics Inc. from 2012 to 2025. Historical debt coverage capacity for Elicio Therapeutics Inc. across 10 annual periods. Check Elicio Therapeutics Inc. (ELTX) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Elicio Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2012–2025)
Elicio Therapeutics Inc. cash flow-to-debt ratio by year from 2012 to 2025. Year-by-year debt coverage analysis for Elicio Therapeutics Inc.. For the full cash flow conversion analysis, see how efficiently does Elicio Therapeutics Inc. generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.53x | $-36.95 Million | $24.23 Million | ▼ -62.5% |
| 2024 | -0.94x | $-37.07 Million | $39.49 Million | ▲ +54.7% |
| 2023 | -2.07x | $-32.69 Million | $15.77 Million | ▼ -28.5% |
| 2022 | -1.61x | $-22.18 Million | $13.75 Million | ▼ -1.1% |
| 2021 | -1.60x | $-23.94 Million | $15.01 Million | ▼ -860.4% |
| 2020 | -0.17x | $-22.89 Million | $137.80 Million | ▲ +79.4% |
| 2019 | -0.81x | $-24.59 Million | $30.47 Million | ▲ +22.4% |
| 2018 | -1.04x | $-8.02 Million | $7.72 Million | ▼ -462.7% |
| 2013 | 0.29x | $1.89 Million | $6.60 Million | ▲ +82.7% |
| 2012 | 0.16x | $1.07 Million | $6.79 Million | — |